Signal active
Organization
Contact Information
Overview
Kandesai is a personalized tumor immunotherapy developer, focusing on the development of immunotherapy platforms based on tumor neoantigens. It has independently developed 3 tumor drug pipelines based on neoantigens and innovative pipelines for liver cirrhosis with independent intellectual property rights. Help patients suppress tumor recurrence and metastasis.
About
Health Care, Pharmaceutical, Medical, Medical Device
2016
51-100
Headquarters locations
Asia
Social
N/A
Profile Resume
Kangdesai Medical Technology headquartered in Asia, operates in the Health Care, Pharmaceutical, Medical, Medical Device sector. The company focuses on Health Care and has secured $125.3M in funding across 16 round(s). With a team of 51-100 employees, Kangdesai Medical Technology is actively contributing to advancements in Health Care. Their latest funding round, Seed Round - Kangdesai Medical Technology, raised $7.8M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
1
5
0
$7.8M
Details
1
Kangdesai Medical Technology has raised a total of $7.8M in funding over 1 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2021 | Seed | 7.8M |
Investors
Kangdesai Medical Technology is funded by 7 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
Beijing Enterprises Medical and Health Industry Group | - | FUNDING ROUND - Beijing Enterprises Medical and Health Industry Group | 7.8M |
Shanghai Starcom Venture Capital Management Center | - | FUNDING ROUND - Shanghai Starcom Venture Capital Management Center | 7.8M |
Kangdesai Medical Technology | - | FUNDING ROUND - Kangdesai Medical Technology | 7.8M |
Shenzhen Baichuan Yingzhi Investment Development | - | FUNDING ROUND - Shenzhen Baichuan Yingzhi Investment Development | 7.8M |
Recent Activity
There is no recent news or activity for this profile.